文献速递其他结缔组织病

验证半定量法评估系统性硬化症相关间质性肺病严重程度与进展:基于标准剂量与低剂量高分辨率CT

Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans.
PubMed 文献 · RMD Open · 2025-02-27

本研究纳入苏黎世65例和奥斯陆90例系统性硬化症患者,验证半定量纤维化范围评估法在高分辨率CT上的内容效度、结构效度、判别力、对变化的敏感性和可行性。纤维化范围与用力肺活量、一氧化碳弥散量和氧饱和度下降显著相关,评定者间与评定者内信度优异,结论支持其用于临床实践。

要点

  • 半定量高分辨率CT纤维化评估与用力肺活量、一氧化碳弥散量及氧饱和度下降显著相关。
  • 评定者间信度κ=0.891、评定者内信度κ=0.996,高分辨率CT定量耗时平均9-15分钟。
  • 判别力与变化敏感性评估仅与一氧化碳弥散量中度相关(r=-0.377,p=0.003)。

核心结论

  • 本研究证实,用于系统性硬化症相关间质性肺病的半定量高分辨率CT纤维化评估满足多数验证标准,支持其用于临床实践,并显示结构评估对功能评估具有附加价值。

研究设计与样本

  • 纳入来自苏黎世和奥斯陆的系统性硬化症患者,采集高分辨率CT图像、肺功能检查(含用力肺活量、一氧化碳弥散量)及6分钟步行试验伴氧饱和度下降数据。
  • 采用内容效度、结构效度、判别力、对变化的敏感性和可行性标准,以及评定者间与评定者内变异性,验证高分辨率CT半定量纤维化范围评估法。

主要发现

  • 共纳入苏黎世65例和奥斯陆90例系统性硬化症患者。
  • 高分辨率CT纤维化范围与用力肺活量(r=-0.517,p<0.001)、一氧化碳弥散量(r=-0.400,p<0.001)和氧饱和度下降(r=-0.500,p<0.001)均呈显著相关。
  • 判别力与变化敏感性评估显示与一氧化碳弥散量中度相关(r=-0.377,p=0.003),但与用力肺活量或氧饱和度下降无显著相关。
  • 评定者间变异性κ=0.891、评定者内变异性κ=0.996,均显示优异信度;高分辨率CT定量平均耗时9-15分钟,可行性高。

关键数值与推荐

  • 高分辨率CT纤维化范围与用力肺活量相关r=-0.517(p<0.001)。
  • 高分辨率CT纤维化范围与一氧化碳弥散量相关r=-0.400(p<0.001)。
  • 高分辨率CT纤维化范围与氧饱和度下降相关r=-0.500(p<0.001)。
  • 判别力与变化敏感性评估与一氧化碳弥散量相关r=-0.377(p=0.003)。
  • 评定者间信度κ=0.891,评定者内信度κ=0.996。

临床怎么用

  • 作者结论支持该半定量高分辨率CT纤维化评估法用于临床实践,并认为结构评估对功能评估具有附加价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While the presence of distinct imaging abnormalities by high-resolution CT (HRCT) defines interstitial lung disease (ILD), there is a relative lack of validated methods to quantify these abnormalities in clinical practice, limiting ILD severity and progression assessments. We aimed to validate a semi-quantitative method for lung fibrosis assessment in patients with systemic sclerosis associated ILD (SSc-ILD) by standard and low-dose HRCT, considering lung structure and function as integral components of ILD evaluation. METHODS: SSc patients from Oslo and Zurich with HRCT images, pulmonary function tests, including forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO) and the 6-minute walk test with oxygen (O2) desaturation were enrolled. We validated the semi-quantitative fibrosis extent method by HRCT using criteria for content and construct validity, discrimination, sensitivity to change and feasibility, as well as inter- and intra-rater variability. RESULTS: 65 SSc patients from Zurich and 90 from Oslo were included. Significant correlations were observed between the extent of fibrosis on HRCT and FVC (r=-0.517, p<0.001), DLCO (r=-0.400, p<0.001) and O2 desaturation (r=-0.500, p<0.001), indicating content, construct and criterion validity. Discrimination and sensitivity to change assessments showed moderate correlation with DLCO (r=-0.377, p=0.003) but not with FVC or O2 desaturation. Inter- and intra-rater variability demonstrated excellent reliability (κ=0.891 and κ=0.996, respectively), with HRCT quantification averaging 9-15 min, indicating high feasibility. CONCLUSION: This study confirms that semi-quantitative fibrosis assessment of HRCT for SSc-ILD meets most validation criteria, supporting its use in clinical practice and showing additive value of structural to functional ILD assessment.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tschalèr L, Jordan S, Aaløkken TM, et al. Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans. RMD Open. 2025. PMID: 40021203. doi:10.1136/rmdopen-2024-004938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。